Main contents starts here
November 4, 2011
Osaka, Japan, November 4, 2011 – Takeda Pharmaceutical Company Limited (“Takeda”) announced today a revision to the consolidated financial forecasts for fiscal year ending March 31, 2012, that were previously announced on July 29, 2011. The revision was made based on the recent trends in business performance.
|(Millions of yen)||(Millions of yen)||(Millions of yen)||(Millions of yen)||(Yen)|
|Revised Forecast (B)||1,540,000||270,000||270,000||170,000||215.36|
Results for Fiscal Year
Ending March 31, 2011
2. Reasons for Revision
The consolidated financial forecasts for fiscal year ending March 31, 2012, have been revised from the previous forecasts (announced at 1st quarter of fiscal 2011 financial results announcement on July 29, 2011), taking the current results into consideration and reflecting a review of foreign exchange rates, in addition to the effect of acquisition of Nycomed. The details can be found at the following URL.
(Website of the Company)
(Website of the Tokyo Stock Exchange, part of listed company information)
The revised forecast for FY2011 includes the effect of acquisition of Nycomed. However, the amount of valuation/allocation for Nycomed’s assets/liabilities and the accounting treatment for the amortization method and its duration may be changed within one year from the acquisition date, according to the business combination accounting standards. The final amount will be settled through the audit by our independent auditor. This forecast includes the Nycomed’s profit and loss impact for 2nd half of fiscal 2011 only, because the acquisition was completed at the end of September 2011.
Skip sub navigation